Maktaba

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.

Authors : Liu C; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.; Zhou F

Subjects: B7-H1 Antigen*/B7-H1 Antigen*/B7-H1 Antigen*/antagonists & inhibitors ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/antagonists & inhibitors

Source: British journal of pharmacology [Br J Pharmacol] 2021 Jul; Vol. 178 (13), pp. 2651-2670. Date of Electronic Publication: 2021 May 04.Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381

Record details

Read Online Read More Add to Saved list

Academic Journal

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

Authors : Kong X; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.; Lu P

Subjects: B7-H1 Antigen/B7-H1 Antigen/B7-H1 Antigen/*genetics ; Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/*therapeutic use ; Neoplasms/Neoplasms/Neoplasms/*therapy

Source: Molecular medicine reports [Mol Med Rep] 2021 May; Vol. 23 (5). Date of Electronic Publication: 2021 Mar 24.Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity.

Authors : Liu C; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei 443001, P.R. China.; Lu J

Subjects: Gene Expression Regulation, Neoplastic* ; Immunomodulation*; B7-H1 Antigen/B7-H1 Antigen/B7-H1 Antigen/*genetics

Source: Molecular medicine reports [Mol Med Rep] 2017 Mar; Vol. 15 (3), pp. 1063-1070. Date of Electronic Publication: 2017 Jan 05.Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.

Authors : Guo Y; Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science And Technology, Wuhan, China.; Yu P

Subjects: B7-H1 Antigen/B7-H1 Antigen/B7-H1 Antigen/*metabolism ; Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*metabolism ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*pathology

Source: PloS one [PLoS One] 2016 May 26; Vol. 11 (5), pp. e0156323. Date of Electronic Publication: 2016 May 26 (Print Publication: 2016).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.

Authors : Man X; Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.; Huang J

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Trastuzumab*/Trastuzumab*/Trastuzumab*/therapeutic use ; Trastuzumab*/Trastuzumab*/Trastuzumab*/pharmacology

Source: Clinical and translational medicine [Clin Transl Med] 2024 May; Vol. 14 (5), pp. e1687.Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet ISSN: 2001-1326

Record details

Read Online Read More Add to Saved list

Academic Journal

Research Progress on the Mechanism of the Antitumor Effects of Cannabidiol.

Authors : Ma L; Department of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Yantai 264003, China.; Liu M

Subjects: Cannabidiol*/Cannabidiol*/Cannabidiol*/pharmacology ; Cannabidiol*/Cannabidiol*/Cannabidiol*/therapeutic use ; Cannabidiol*/Cannabidiol*/Cannabidiol*/chemistry

Source: Molecules (Basel, Switzerland) [Molecules] 2024 Apr 24; Vol. 29 (9). Date of Electronic Publication: 2024 Apr 24.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

Read Online Read More Add to Saved list

Academic Journal

Remnant cholesterol is an effective biomarker for predicting survival in patients with breast cancer.

Authors : Shi J; Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.; National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/mortality ; Cholesterol*/Cholesterol*/Cholesterol*/blood ; Lipoproteins*

Source: Nutrition journal [Nutr J] 2024 Apr 22; Vol. 23 (1), pp. 45. Date of Electronic Publication: 2024 Apr 22.Publisher: BioMed Central Country of Publication: England NLM ID: 101152213 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2891

Record details

Read Online Read More Add to Saved list

Academic Journal

The impact of lipidome on breast cancer: a Mendelian randomization study.

Authors : Cao Y; Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan, Beijing, 100144, China.; Ai M

Subjects: Lipidomics* ; Neoplasms*; Bayes Theorem

Source: Lipids in health and disease [Lipids Health Dis] 2024 Apr 15; Vol. 23 (1), pp. 109. Date of Electronic Publication: 2024 Apr 15.Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X

Record details

Read Online Read More Add to Saved list

Academic Journal

Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.

Authors : Wang T; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.

Subjects: CD47 Antigen* ; Neoplasms*/Neoplasms*/Neoplasms*/pathology; Animals

Source: Journal of translational medicine [J Transl Med] 2024 Mar 01; Vol. 22 (1), pp. 220. Date of Electronic Publication: 2024 Mar 01.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876

Record details

Read Online Read More Add to Saved list

Academic Journal

UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies.

Authors : Ma L; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.; Shanghai Innostar Bio-Tech Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai 201203, China.

Subjects: Prodrugs*/Prodrugs*/Prodrugs*/chemistry ; Neoplasms* ; Cysteine Endopeptidases*

Source: Molecules (Basel, Switzerland) [Molecules] 2024 Feb 08; Vol. 29 (4). Date of Electronic Publication: 2024 Feb 08.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity.

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.

Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.

Research Progress on the Mechanism of the Antitumor Effects of Cannabidiol.

Remnant cholesterol is an effective biomarker for predicting survival in patients with breast cancer.

The impact of lipidome on breast cancer: a Mendelian randomization study.

Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.

UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies.